zambia herald : Latest News and In-depth Analysis
PORT VILA,Vanuatu,March 17,2025-- Vantage Markets participated as a Titanium Sponsor at Money Expo Mexico 2025,held on February 26-27. The event,known as one of the most significant gatherings for tr
NEW YORK,March 18,2025-- After selling out in just two days,COSRX\'s highly anticipated The Ceramide Skin Barrier Moisturizer has become a sensation in the skincare world. Fans and skincare enthusiast
URUMQI,China,March 17,2025--On March 14,State GridXinjiang Information &TelecommunicationCompany,leveraging the integration of party building and business operations as a platform,organized a &quo
SINGAPORE,March 18,2025-- Singapore\'s tourism and retail industries are undergoing a transformation,with Chinese tourists increasingly relying on digital platforms like Meituan Dianping and Xiaohongs
BEIJING,March 18,2025-- Farmers are busy pollinating cherry blossoms in the cherry greenhouses ofQicun Town,Shizhong District in Zaozhuang City,east China\'s Shandong Province,paving the way for a bum
In two engaging discussions,HONOR sheds light on the envisioned future that the HONOR ALPHA PLAN will achieve
CAMBRIDGE,Mass.,ROTTERDAM,Netherlands and SHANGHAI,Feb. 20,2025-- Harbour BioMed (HKEX: 02142,the "Company"),a global biopharmaceutical company committed to the discovery,development and co
KYOTO,Japan,Feb. 20,2025-- Nuvoton Technology Corporation Japan (NTCJ) has developed new industrial 17-cell BM-ICs "KA49701A" and "KA49702A" for 48V batteries. Mass production will
STOCKHOLM,Feb. 20,2025-- The shareholders ofTelefonaktiebolaget LM Ericsson (reg. no 556016-0680) (the "Company" or "Ericsson") are invited to participate in the Annual General Mee
MELBOURNE,Australia and INDIANAPOLIS,Ind.,Feb. 20,2025--Telix Pharmaceuticals Limited (ASX: TLX,Nasdaq:TLX,Telix,the Company) today announces its financial results for the year ended 31 December 2024
STOCKHOLM,Feb. 21,2025-- Autoliv,Inc. (NYSE: ALV) (SSE: ALIV.sdb),the worldwide leader in automotive safety systems,has filed with the Securities and Exchange Commission (SEC) its 2024 Annual Report o
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1
